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 The proliferative capacity of smooth
muscle cells (SMC) during neointima
formation is prevented by everolimus-
coated drug-eluting stents.
 Everolimus failed to inhibit neointima
formation by in mice overexpressing
telomerase reverse transcriptase (TERT).
 Everolimus reduced TERT-dependent SMC
proliferation through inhibition of
Ets-1–dependent promoter activation.
 The inhibition of TERT-dependent SMC
proliferation by everolimus occurred as a
result of a G1/S-phase arrest, rather
than telomerase shortening.
 Chromatin immunoprecipitation assays
demonstrated that TERT induced E2F
binding to S-phase gene promoters and
supported histone acetylation.
 These studies identify a novel mitogenic
pathway in SMC that depends on the
epigenetic activation of S-phase gene
promoters by TERT.ar Research Center, University of
es of Health grant RO1HL111040
contents of this paper to disclose.
ABBR EV I A T I ON S
AND ACRONYMS
ChIP = chromatin
immunoprecipitation
MCM7 = minichromosome
maintenance protein 7
mTOR = mammalian targe
rapamycin
PCNA = proliferating cell
nuclear antigen
RB = retinoblastoma prote
SMC = vascular smooth mu
cells
TBP = TATA binding prote
TERT = telomerase revers
transcriptase
TERTtg = telomerase reve
transcriptase–overexpressi
transgenic
WT = wild type
Aono et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 1 - 2 , 2 0 1 6
Telomerase Targeting by Everolimus J A N U A R Y / F E B R U A R Y 2 0 1 6 : 4 9 – 6 0
50SUMMARYt of
in
scl
in
e
rse
ngProliferation of smooth muscle cells (SMCs) during neointima formation is prevented by drug-eluting stents. The repli-
cative capacity of mammalian cells is enhanced by telomerase expression; however, the contribution of telomerase to the
proliferative response underlying neointima formation and its potential role as a pharmacological target are unknown.
The present study investigated the mechanisms underlying the mitogenic function of telomerase, and tested the hy-
pothesis that everolimus, which is commonly used on drug-eluting stents, suppresses SMC proliferation by targeting
telomerase. Inhibition of neointima formation by everolimus was lost in mice overexpressing telomerase reverse tran-
scriptase (TERT), indicating that repression of telomerase confers the anti-proliferative efﬁcacy of everolimus. Everolimus
reduced TERT expression in SMC through an Ets-1-dependent inhibition of promoter activation. The inhibition of TERT-
dependent SMC proliferation by everolimus occurred in the absence of telomere shortening but rather as a result of a
G1/S-phase arrest. Although everolimus failed to inhibit phosphorylation of the retinoblastoma protein as the gate-
keeper of S-phase entry, it potently repressed downstream target genes. Chromatin immunoprecipitation assays
demonstrated that TERT induced E2F binding to S-phase gene promoters and supported histone acetylation. These
effects were sensitive to inhibition by everolimus. These results characterize telomerase as a previously unrecognized
target for the antiproliferative activity of everolimus, and further identify a novel mitogenic pathway in SMC that depends
on the epigenetic activation of S-phase gene promoters by TERT. (J Am Coll Cardiol Basic Trans Sci 2016;1:49–60)
© 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I n addition to endothelial dysfunction and in-ﬂammation, proliferation of vascular smoothmuscle cell (SMC) constitutes an essential com-
ponent for atherosclerosis formation and neointimal
remodeling (1). Once luminal obstruction in the
course of atherosclerotic remodeling occurs, revascu-
larization procedures represent primary treatment
strategies (2). However, the clinical success of these
procedures is limited by post-angioplasty restenosis,
coronary artery bypass graft failure, and transplant
vasculopathy. Considering the critical role of SMC
proliferation in the pathophysiology of these treat-ement failures, the implantation of drug-
eluting stents has become standard-of-care
to prevent restenosis after angioplasty (3).
Among the widely employed mammalian
target of rapamycin (mTOR) inhibitors,
recent clinical evidence has indicated that
particularly second-generation, everolimus-
eluting stents provide improved revasculari-
zation outcomes (4,5). Although everolimus
potently inhibits neointima formation (6)
and SMC proliferation (7), the detailed molec-
ular mechanisms by which mTOR inhibitors
elicit their antiproliferative efﬁcacy and pre-
vent cell cycle progression in SMC remain
controversial. Early studies indicated that
mTOR inhibitors induce G1 cell cycle arrest
by targeting the retinoblastoma protein (RB),
the key gatekeeper of the cell cycle, which re-
presses S-phase gene expression induced by
the transcription factor E2F (8). However,more recent evidence in SMC that are deﬁcient for
the RB protein have indicated that mTOR inhibitors
may repress cell cycle progression independently of
RB protein phosphorylation (9). Considering this con-
troversy, the precise mechanisms by which commonly
implanted everolimus-eluting stents prevent in-stent
restenosis remain elusive.
By maintaining the stability of telomeres, repetitive
deoxyribonucleic acid (DNA)-protein complexes that
protect the ends of chromosomes, telomerase is rate
limiting for cell proliferation and tissue renewal (10).
Overexpression of the catalytic subunit telomerase
reverse transcriptase (TERT) confers a virtually un-
limited replicative capacity (11). In contrast, most so-
matic cells are thought to repress TERT, resulting in
telomere shortening and limited replicative potential
(12). However, accumulating evidence revealed that
TERT is inducible in response to various environ-
mental cues (13), which enhance proliferative re-
sponses during tissue renewal (10). Similarly as in
other somatic tissues, we (14–16) and others (17) have
previously reported that TERTexpression is induced in
proliferating SMC and in response to neointima and
atherosclerosis formation. However, whether TERT
expression in the vascular wall causes neointima for-
mation and the transcriptional mechanisms by which
TERT induces aberrant SMC proliferation remain
unknown. Moreover, the possibility that TERT con-
stitutes an alternative molecular target for the
RB-independent antiproliferative efﬁcacy of mTOR
inhibitors on drug-eluting stents has previously not
been investigated. Here, we demonstrate that TERT
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51expression bypasses RB phosphorylation as the
common cell cycle checkpoint to directly activate an
S-phase gene expression program through epigenetic
modiﬁcation. Consistent with this mitogenic activity
of TERT, we further characterize TERT-dependent
downstream histone acetylation of S-phase genes as
a previously unrecognized mechanism underlying
the inhibition of SMC proliferation by everolimus.
METHODS
CELL CULTURE. Primary human coronary artery
vascular smooth muscle cells were purchased from
Lonza (Allendale, New Jersey). Primary mouse
vascular smooth muscle cells were isolated from 8- to
12-week-old littermate wild-type (WT) and telome-
rase reverse transcriptase–overexpressing transgenic
(TERTtg) mice (18) as previously described (15). The
SMC were treated with everolimus as indicated.
ENDOTHELIAL DENUDATION INJURY. All animal
studies were approved by the Institutional Animal
Care and Use Committee at the University of Ken-
tucky. Guidewire-induced endothelial denudation
injuries were performed on the femoral arteries of 8-
to 12-week-old male littermate WT and TERTtg mice
(15). Immediately after injury, the perivascular area of
the femoral artery was treated with vehicle or 100 mg
of everolimus. After 28 days, femoral arteries were
removed and stained with an elastic Verhoeff-van
Gieson staining kit.
For a more detailed methods summary, please see
the Supplemental Appendix.
RESULTS
EVEROLIMUS INHIBITS SMC PROLIFERATION AND CELL
CYCLE PROGRESSION. Due to the well-established
antimitotic activity of mTOR inhibitors, sirolimus (8)
and everolimus (7) constitute primary agents used
on ﬁrst- and second-generation drug-eluting stents,
respectively. Therefore, we ﬁrst evaluated the efﬁ-
cacy of everolimus and sirolimus to inhibit SMC pro-
liferation in vitro. Consistent with a previous study
(7), everolimus dose-dependently inhibited SMC
proliferation (Figure 1A). Compared with everolimus,
the previously reported antiproliferative efﬁcacy of
sirolimus (8) was limited to higher equimolar doses
(Figure 1B). To further determine the mechanism by
which everolimus prevents SMC proliferation, we
next examined cell cycle distribution. As depicted in
Figure 1C, everolimus inhibited mitogen-induced
G1/S phase progression. On the basis of this
ﬁnding, we investigated whether everolimus sup-
pressed phosphorylation of the RB protein as therate-limiting step for G1/S-phase progression. RB
phosphorylation releases the transcription factor E2F,
which in turn activates target genes required for DNA
synthesis (19). However, surprisingly, everolimus
inhibited neither site-speciﬁc ser807/811 nor total
phosphorylation of the RB protein (Figure 1D),
although it caused potent inhibition of G1/S-phase
progression. These results indicate that everolimus
inhibits cell cycle progression through a mechanism
independent of RB phosphorylation.
EVEROLIMUS INHIBITS SMC PROLIFERATION THROUGH
TRANSCRIPTIONAL REPRESSION OF TELOMERASE.
Whereas RB phosphorylation promotes cell prolifera-
tion through release of the S-phase transcription factor
E2F, telomerase overexpression endows cells with an
unlimited replicative potential by overcoming the
limitations of senescence (10,11). Although this
mitogenic activity of telomerase was long thought to
result from its ability to maintain telomeres, recent
evidence indicates that TERT enhances proliferation
through mechanisms independent of telomere elon-
gation (20,21). Considering this evidence and our
previous observation that telomerase is required for
SMC proliferation (14,15), we hypothesized that the
antimitotic activity of everolimus may depend on
the repression of TERT. To address this question, we
evaluated the antiproliferative efﬁcacy of everolimus
in SMC isolated from mice overexpressing a murine
TERT transgene (18). As depicted in Figure 2A,
expression of the murine TERT transgene induced
SMC proliferation even in the absence of mitogenic
stimulation. Furthermore, TERT expression pre-
vented the inhibition of mitogen-induced SMC
proliferation by everolimus, indicating that TERT
constitutes an important target for the growth ar-
rest induced by everolimus. On the basis of these
ﬁndings, we next investigated whether TERT
expression is inhibited by everolimus in SMC.
Western blotting (Figure 2B) and immunohisto-
chemistry (Figure 2C) revealed that everolimus
dose-dependently inhibited TERT protein expres-
sion. Consistent with a primarily transcriptional
regulation of TERT in SMC (14,15), everolimus
repressed mitogen-induced TERT messenger ribonu-
cleic acid expression (Figure 2D) and promoter activity
(Figure 2E). Collectively, these experiments conﬁrm
that everolimus inhibits SMC proliferation through
transcriptional repression of mitogen-induced TERT
expression.
EVEROLIMUS REPRESSES Ets-1–DEPENDENT
TRANSACTIVATION OF THE TERT PROMOTER. Having
characterized TERT as a transcriptional target for
everolimus, we next investigated the mechanisms
FIGURE 1 Everolimus Inhibits SMC Proliferation and Cell Cycle Progression
(A and B) Primary human coronary artery vascular smooth muscle cells (hSMC) were serum-deprived () and treated with vehicle or the indicated doses of
everolimus (A) or sirolimus (B) in growth medium. Cell counts are expressed as mean  SEM (n ¼ 12 samples/group) relative to quiescent hSMC. (A) Signiﬁcance
levels versus quiescent cells (): growth medium þ vehicle, *p < 0.001; growth medium þ 0.1 mmol/l everolimus, *p ¼ 0.007; growth medium þ 1 mmol/l
everolimus, *p ¼ 0.009. Signiﬁcance levels versus growth medium þ vehicle: growth medium þ 10 mmol/l everolimus, #p < 0.001; growth medium þ 25 mmol/l
everolimus, #p < 0.001. (B) Signiﬁcance levels versus quiescent cells (): growth medium þ vehicle, *p < 0.001; growth medium þ 0.1 mmol/l sirolimus,
*p ¼ 0.010; growth medium þ 1 mmol/l sirolimus, *p ¼ 0.008; growth medium þ 10 mmol/l sirolimus, *p ¼ 0.008; growth medium þ 25 mmol/l sirolimus,
*p ¼ 0.009. (C) Deoxyribonucleic acid histograms showing cell cycle distribution of hSMC after treatment with 10 mmol/l everolimus. (D) Western blotting for
phosphorylated (phospho) retinoblastoma protein (RB), total RB, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in cell lysates isolated from hSMC. The
autoradiograms shown represent 3 independently performed experiments using different cell preparations. Values are normalized to GAPDH and expressed as mean
 SEM (n ¼ 6 samples/group) relative to quiescent hSMC (*p < 0.001 versus starvation).
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FIGURE 2 Everolimus Inhibits SMC Proliferation Through Transcriptional Repression of Telomerase
D E
A B
C
(A) Cell proliferation assay in primary murine vascular smooth muscle cells (mSMC) isolated from wild-type (WT) or telomerase reverse transcriptase–overexpressing
transgenic (TERTtg)mice. Cellswere serum-deprived () and treatedwith vehicle or 10mmol/l everolimus in 20%fetal bovine serum (FBS). Values are expressed as themean
 SEM (n¼ 12 samples/group) relative to quiescent WT mSMC. Signiﬁcant levels versus quiescent cells (): FBSþ vehicle (WT), *p¼ 0.008; FBSþ vehicle (TERTtg), *p<
0.001; FBSþ 10 mmol/l everolimus (TERTtg); *p<0.001. Signiﬁcance levels versusWT: quiescent cells, #p<0.001; FBSþ vehicle, #p<0.001; FBSþ 10 mmol/l everolimus,
#p<0.001. (B)Westernblotting forTERTexpression innuclearextracts isolated fromhSMCtreatedwitheverolimus.DensitometricdataareexpressedasTERTnormalized to
TATAbindingprotein (TBP) andpresented asmean SEMfold-increase over vehicle from3 independently performedexperiments (n¼9samples/group). Signiﬁcance levels
versus quiescent cells (): growthmediumþ vehicle, *p<0.001; growthmediumþ0.1 mmol/l everolimus, *p<0.001; growthmediumþ 1 mmol/l everolimus, *p<0.001;
growth medium þ 10 mmol/l everolimus, *p < 0.001. Signiﬁcance level versus growth medium þ vehicle: growth medium þ 10 mmol/l everolimus, #p ¼ 0.022. (C)
Immunostaining for TERTexpression (green) inWTmSMCtreatedwith 10mmol/l everolimus. 40-6-diamidino-2-phenylindole (DAPI)wasused fornuclear staining. Imagesare
representative of 3 independently performed experiments. (D) TERT mRNA expression in hSMC treated with 10 mmol/l everolimus analyzed by real-time PCR. Values are
normalized to the housekeeping gene TBP and expressed as mean SEM (n¼ 12 samples/group) relative to quiescent hSMC (*p¼ 0.047 versus quiescent cells). (E) hSMC
were transfected with a reporter construct driven by the full length TERT promoter. Following transfection, cells were treated with everolimus and analyzed for luciferase
activity. Values are mean  SEM (n ¼ 12 samples/group) relative to luciferase activity of quiescent hSMC (*p < 0.001 versus quiescent cells).
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FIGURE 3 Everolimus Represses Ets-1–Dependent Transactivation of the
TERT Promoter
hSMC were treated with 10 mmol/l everolimus and stimulated with growth medium.
Chromatin was harvested for ChIP assays using an antibody raised against Ets-1. Nonim-
mune IgG was used as a negative control. The graph depicts quantiﬁcation of immuno-
precipitated chromatin by real-time PCR using primer pairs that cover the Ets-1 site in the
proximal TERT promoter. Cycle threshold (Ct) values were normalized to Ct values of input
samples and are expressed as mean  SEM (n ¼ 12 samples/group). Signiﬁcance levels
versus quiescent cells (starvation): growth medium þ vehicle, *p ¼ 0.007; growth
medium þ 10 mmol/l everolimus, *p ¼ 0.009. Signiﬁcance levels versus growth medium þ
vehicle, #p ¼ 0.041.
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TERT promoter. Inducible TERT transcription during
mitogenic responses of SMC is mediated through
transactivation of 2 adjacent Ets-1 consensus motifs
located at -23 and -18 within the TERT promoter (15).
To analyze whether everolimus inhibits recruitment
of Ets-1 binding to the endogenous TERT promoter,
we employed chromatin immunoprecipitation (ChIP)
assays. PCR ampliﬁcation using primer pairs that
cover the Ets-1 site at -23 in the TERT promoter
demonstrated that everolimus suppressed Ets-1
binding to the TERT promoter (Figure 3). These data
conﬁrm that everolimus attenuates TERT transcrip-
tion by inhibiting Ets-1 recruitment to the TERT
promoter.
EVEROLIMUS SILENCES E2F TARGET GENE EXPRESSION
WITHOUT INDUCING TELOMERE ATTRITION OR
SENESCENCE. The observation that everolimus in-
hibits SMC proliferation through transcriptional
repression of TERT raised the question of how TERT
supports the mitogenic response. Furthermore, our
data showing that everolimus induces G1 cell cycle
arrest without inhibiting RB phosphorylation indicate
that TERT signaling may feed directly into the S phase
through a previously unknown mechanism, which is
inhibited by everolimus. To address these questions,we assessed whether the antiproliferative effect and
the repression of TERT by everolimus are associated
with telomere attrition. Quantiﬁcation of telomere
lengths revealed no telomere attrition in SMC treated
with everolimus (Supplemental Figures 1A and 1B).
Consistent with these data, everolimus did not induce
senescence-associated b-galactosidase activity in
everolimus-treated SMC (Supplemental Figure 1C).
These results indicate that the antiproliferative ac-
tivity of everolimus is mediated through TERT
repression; however, this inhibition of SMC prolifer-
ation by everolimus does not require telomere
attrition.
Having conﬁrmed a telomere-length independent
mechanism, we next addressed the mechanisms by
which everolimus-mediated TERT repression induced
cell cycle arrest. As discussed earlier, the primary
mechanism underlying cell cycle progression in-
volves phosphorylation of the RB protein, release of
the E2F transcription factor, and subsequent S-phase
gene transcription of E2F target genes (19). Because
everolimus inhibited mitogen-induced G1/S-phase
progression independently of RB phosphorylation,
we ﬁrst investigated whether everolimus attenuates
the expression of downstream E2F target genes,
which are required for S-phase entry. As shown in
Figures 4A and 4B, messenger ribonucleic acid and
protein expression levels of the bona ﬁde E2F tar-
get genes minichromosome maintenance protein
(MCM)-7, Cyclin A, and proliferating cell nuclear an-
tigen (PCNA) were silenced in response to everolimus
treatment, although RB phosphorylation was not
affected by the drug. Similarly, everolimus did not
inhibit E2F protein expression (Supplemental
Figure 2). These data suggest that the mechanism
underlying everolimus-induced G1 arrest is mediated
by TERT repression, bypasses RB phosphorylation,
and acts directly on the transcription of E2F target
genes causing altered S-phase gene expression.
EVEROLIMUS SILENCES E2F TARGET GENES
THROUGH TERT-DEPENDENT EPIGENETIC HISTONE
MODIFICATION. TERT has previously been described
to induce gene expression through direct chromatin
activation at target gene promoters and interaction
with transcription factors (22). To investigate whether
TERT activates E2F-dependent transcription, we next
employed again SMC isolated from TERTtg mice. As
depicted in Figure 5A, constitutive TERT expression
induced the primary E2F target gene MCM7. Although
everolimus potently inhibited mitogen-induced
MCM7 expression, this efﬁcacy was completely lost
in SMC overexpressing TERT. Similar data were ob-
tained for the E2F target genes PCNA and Cyclin
A (data not shown). Using ChIP experiments, we
FIGURE 4 Everolimus Silences E2F Target Gene Expression
hSMC were treated with 10 mmol/l everolimus and stimulated with growth medium. (A) Minichromosome maintenance protein 7 (MCM7), Cyclin A, and
proliferating cell nuclear antigen (PCNA) mRNA expression levels were analyzed by real-time PCR and normalized to transcript levels of the housekeeping
gene TBP. Data are presented as mean  SEM (n ¼ 9 samples/group) relative to quiescent hSMC. Signiﬁcance levels versus quiescent cells: MCM7,
*p < 0.001; Cyclin A, *p < 0.001; PCNA, *p ¼ 0.008. (B) Western blotting for MCM7, Cyclin A, and PCNA expression in hSMC treated with everolimus.
Densitometric quantiﬁcation from 3 independent experiments was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and expressed
as mean fold increase  SEM (n ¼ 6 samples/group) relative to quiescent hSMC. Signiﬁcance levels versus quiescent cells: MCM7, *p < 0.001; Cyclin A,
*p < 0.001; PCNA, *p ¼ 0.006. Signiﬁcance levels versus growth medium þ vehicle: MCM7, #p < 0.001; Cyclin A, #p < 0.001; PCNA, #p ¼ 0.032.
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FIGURE 5 Everolimus Silences E2F Target Genes Through TERT-Dependent Epigenetic Histone Modiﬁcation
(A) Western blotting for MCM7 in WT and TERTtg mSMC treated with 10 mmol/l everolimus in 20% fetal bovine serum (FBS). Densitometric quantiﬁcation from 3 in-
dependent experiments was normalized to GAPDH and expressed as mean fold increase  SEM (n ¼ 6 samples/group) relative to quiescent WT mSMC. Signiﬁcance levels
versus quiescent cells: *p¼0.041. Signiﬁcance levels versusWT: quiescent cells, #p¼0.018; FBSþ vehicle, #p¼0.046; FBSþ 10 mmol/l everolimus, #p¼0.012. B and C,
HEK293 cells were transfected with a TERT expression vector (TERT) or empty vector (control). Cells were serum-deprived () and treated with vehicle or 10 mmol/l
everolimus in 20% FBS. Chromatin was harvested for chromatin immunoprecipitation assays using antibodies raised against: (B) E2F-1 (signiﬁcance levels versus quiescent
cells: *p¼0.045. Signiﬁcance levels versus control: quiescent cells, #p<0.001; FBSþ vehicle, #p< 0.001; FBSþ 10 mmol/l everolimus, #p<0.001) or (C) acetyl-histone
H3 (Lys9) (signiﬁcance levels versus quiescent cells: *p ¼ 0.048. Signiﬁcance levels versus control: quiescent cells, #p ¼ 0.034; FBS þ vehicle, #p ¼ 0.043; FBS þ 10
mmol/l everolimus, #p ¼ 0.038). Nonimmune IgG was used as a negative control value. Quantiﬁcation of immunoprecipitated chromatin was performed by real-time PCR
using primer pairs that cover the E2F-1 site in the proximal MCM7 promoter. Ct values were normalized to Ct values of input samples and are expressed as mean SEM (n¼
12 samples/group) relative to quiescent cells transfected with empty vector. Abbreviations as in Figures 1 and 3.
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57further conﬁrmed that ectopic TERT expression
(Supplemental Figure 3) increases E2F occupancy of
the MCM7 promoter and abolishes the inhibition of
E2F recruitment induced by everolimus (Figure 5B).
Considering that TERT has been suggested to activate
chromatin allowing subsequent transcription factor
binding (22), we hypothesized that TERT facilitates
E2F binding through chromatin modiﬁcation rather
than by increasing E2F availability. In support of this
hypothesis, TERT overexpression did not increase
E2F levels (Supplemental Figure 4). Moreover,
ectopic E2F expression using adenoviral transduction
did not reverse the inhibition of SMC proliferation by
everolimus, indicating that E2F does not constitute a
primary target for everolimus and that, even under
conditions of abundant E2F availability, everolimus
inhibits SMC proliferation (Supplemental Figure 5).
These data could be reconciled through a mechanistic
model in which everolimus represses TERT-mediated
chromatin activation, thereby restricting subsequent
E2F binding to the target promoter. Consistent with
this model, TERT expression induced histone acety-
lation at the E2F target site and reversed the inhibi-
tion of histone acetylation observed in response to
everolimus (Figure 5C).
TERT OVEREXPRESSION ABOLISHES THE ANTI-
PROLIFERATIVE EFFECT OF EVEROLIMUS ON
NEOINTIMA FORMATION. Finally, to provide in vivo
conﬁrmation that the antiproliferative effect of
everolimus may be attributed to the repression of
TERT, we induced endothelial denudation injuries in
WT and TERTtg mice. As depicted in Figures 6A
and 6B, endovascular injury resulted in concentric
neointima formation in WT mice treated with vehicle.
As expected, everolimus treatment signiﬁcantly
attenuated neointima formation. Consistent with a
key role of TERT in inducing SMC proliferation
in vitro, neointima formation was increased in
TERTtg mice. However, the inhibition of neointima
formation in response to everolimus was abolished in
TERTtg mice. These ﬁndings establish a key role of
TERT in neointima formation and characterize TERT
as previously unrecognized primary target for the
antiproliferative efﬁcacy of everolimus.
DISCUSSION
Everolimus-eluting stents constitute the most widely
utilized stent platform to prevent restenosis after
coronary angioplasty (4,5). Although more than
800,000 stents are implanted annually in the United
States, the molecular mechanisms by which mTOR
inhibitors prevent restenosis remain controversial. In
cultured rat aortic SMC, sirolimus and everolimusprevent mitogen-induced phosphorylation of RB as
a key step for this transition (7–9). However, using
primary human coronary artery SMC isolated from
in-stent restenotic lesions, Rosner et al. (9) have
previously provided compelling evidence that
sirolimus inhibits the progression of the cell cycle
independently of RB. Therefore, the lack of an overt
reduction of RB phosphorylation by everolimus at
concentrations that inhibit cell cycle progression in
our experiments using human coronary artery SMC is
consistent with an RB-independent inhibition of
G1/S phase progression by everolimus. Importantly,
these discrepant ﬁndings point to distinct proliferative
mechanisms between primary human coronary SMC
and rat aortic SMC, and suggest that human coronary
SMC, in particular those isolated from in-stent rest-
enotic lesions, may be able to escape common check-
points and maintain alternative mechanisms that
signal toward S-phase and mitogenic gene expression.
It currently remains unknown whether the
increased expression of TERT during neointima for-
mation contributes to the proliferative response
(14,15,17). Using a transgenic model of TERT over-
expression, our data establish that constitutive TERT
expression accelerates neointima formation. We
further show that the well-established inhibition of
neointima formation by everolimus is lost with
constitutive TERT expression. Therefore, these data
provide the ﬁrst evidence to suggest a fundamental
role of TERT expression during neointima formation
and characterize TERT as a key molecular target
for antiproliferative efﬁcacy of everolimus. It has
previously been reported that inhibition of telo-
merase activity using oligonucleotides inhibits SMC
proliferation in vitro (17). Using small interfering
ribonucleic acid and TERT overexpression ap-
proaches (14,15), our own research has further
conﬁrmed that TERT is necessary and sufﬁcient for
SMC proliferation in vitro. However, the detailed
molecular mechanisms by which TERT induces SMC
proliferation have previously not been addressed and
remain unknown.
Our data illustrate repression of mitogen-induced
TERT promoter activity as the key mechanism
by which everolimus inhibits TERT expression.
Although certain cancer and stem cells constitutively
express TERT, quiescent somatic cells express low
levels of TERT resulting in telomere shortening and
impaired self-renewal (12). However, recent studies
revealed that TERT is primarily regulated at the
transcriptional level and inducible in response to
mitogenic stimulation (13). This inducible TERT
expression has been observed in multiple somatic
tissues and demonstrated to enhance cell function
FIGURE 6 TERT Overexpression Prevents the Antiproliferative Effect of Everolimus on Neointima Formation
(A) Endothelial denudation injury was performed in femoral arteries of WT (n ¼ 16) and TERTtg (n ¼ 16) mice treated with vehicle or ever-
olimus. Tissues were harvested 28 days after injury, and elastic Verhoeff-van Gieson staining was performed to visualize the internal and
external elastic lamina. (B) Intima to media ratio was calculated as the intimal area divided by medial area. Data are presented as median and
quartiles (signiﬁcance level versus vehicle: *p ¼ 0.046. Signiﬁcance level versus WT: vehicle, #p ¼ 0.048; Everolimus; #p ¼ 0.034).
Magniﬁcation  100; scale bar ¼ 50 mm. Abbreviations as in Figure 2.
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58during the proliferative response of tissue renewal
(10). Similarly as in other somatic tissues, we (14,15)
and others (17) have previously reported that TERT
expression is induced in response to growth factor
secretion during injury of the vasculature. TERTpromoter activation during mitogenic stimulation
of SMC is mediated by 2 adjacent Ets-1 motifs at
-23 and -18 (15), and Ets-1 expression is induced
during neointimal SMC proliferation (23). Consistent
with our recent ﬁnding of Ets-1–dependent TERT
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Increased
expression of the telomerase component TERT in response to
vascular injury may serve a mitogenic function and accelerate
aberrant neointima formation. In pre-clinical models, this induc-
ible TERT expression constitutes an important target for the well-
established antiproliferative efﬁcacy of everolimus.
TRANSLATIONALOUTLOOK: Future studies are warranted to
investigate whether everolimus-eluting stent systems repress TERT
after implantation in human coronary arteries and whether it is
feasible to target TERT selectively in SMC while preserving
re-endothelialization.
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59promoter transactivation during SMC proliferation
(15), ChIP experiments conﬁrmed Ets-1 binding to
these consensus sites. Moreover, our data revealed
that everolimus reduces Ets-1 binding to the endog-
enous TERT promoter in SMC. mTOR inhibitors have
previously been demonstrated to attenuate Ets-1
protein expression in SMC (24), suggesting that the
repression of TERT transcription by everolimus may
be mediated at least in part through an inhibition of
Ets-1 expression.
Everolimus-induced repression of TERT and the
ensuing inhibition of SMC proliferation do not involve
mechanisms that are dependent on telomere short-
ening or cellular senescence. In support of this notion,
previous work has conﬁrmed that TERT induces cell
proliferation independently of its reverse transcrip-
tase activity and ability to elongate telomeres (25,26).
We further ﬁnd that everolimus treatment of SMC in-
duces cell cycle arrest in the G1 phase and is associated
with altered downstream E2F-dependent S-phase
gene expression. Conversely, TERT expression in
SMC isolated from mice overexpressing a TERT
transgene induces E2F-dependent transcription of
MCM7, PCNA, and Cyclin A in SMC and reverses the
repression of these bona ﬁde S-phase genes by
everolimus. Consistent with these data, ectopic
TERT expression drives stem cells into S phase and
induces the activity of E2F in epithelial cells (27,28).
Our data extend this prior research and indicate that
TERT enhances E2F recruitment to the chromatin of
its target genes, whose protein products are required
for DNA synthesis during S phase.
The molecular mechanisms that link TERT to gene
transcription and increase E2F binding at S-phase gene
promoters in our experiments remain elusive. How-
ever, recent analyses have documented that TERT in-
duces differential gene expression and activates
speciﬁc transcriptional programs independently of its
catalytic activity (20,21). The broader changes in gene
expression affected by TERT raised the possibility that
TERT activates transcription through epigenetic
mechanisms. Indeed, we observed that TERT expres-
sion induces histone acetylation at E2F motifs, which
represents a reasonable mechanism for the increased
E2F binding. Furthermore, ectopic E2F expression
failed to reverse the inhibition of cell proliferation by
everolimus, which could be explained by the acquisi-
tion of a silenced chromatin state at E2F sites in cells
treated with everolimus and subsequent depletion of
TERT. The hypothesis of an epigenetic mechanism is
supported not only by our data demonstrating that
TERT overexpression induces histone acetylation at
E2F target sites, but also by previous work, in which
TERT has been suggested to activate the chromatinat Wnt-dependent promoters in stem cells (22).
Interestingly, TERT itself appears to be recruited to
chromatin at selective transcription factor binding
sites, where it associates with chromatin-modifying
proteins (22). Alternatively, TERT may increase E2F
binding through protein stabilization at the chromatin,
which has recently been reported for myc-dependent
gene transcription (29). Therefore, characterization of
the speciﬁc chromatin signature at TERT-activated
transcription sites will be necessary in future studies
to determine the detailed mechanisms by which TERT
modulates gene transcription.
CONCLUSIONS
We identiﬁed TERT as a previously unrecognized
activator of an S-phase gene expression program.
In response to mitogenic stimulation, TERT facilitates
E2F transcription factor binding by supporting histone
acetylation at its target promoters leading to SMC
proliferation. We further establish that everolimus
transcriptionally repressed TERT, which subsequently
silences downstream E2F target gene expression.
Collectively, these studies illustrate a novel mitogenic
mechanism underlying SMC proliferation and identify
TERT repression as a principal mechanism for the
antiproliferative efﬁcacy of everolimus.
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